ظ…ط­طھط§ط¬
ظ…ط­طھط§ط¬
ظ…ط­طھط§ط¬
دردشة
ظ…ط­طھط§ط¬ العاب
ظ…ط­طھط§ط¬ التسجيل
ظ…ط­طھط§ط¬ ماسنجر
ظ…ط­طھط§ط¬ اعلن معنا
ظ…ط­طھط§ط¬ الاتصال بنا
ظ…ط­طھط§ط¬
ظ…ط­طھط§ط¬
ظ…ط­طھط§ط¬ ظ…ط­طھط§ط¬


العاب محتاج
محتاج   محتاج
عـودة للخلف   منتديات محتاج > منتديات شبابيات محتاج > نفحات إيمانيه > اناشيد mp3 - اناشيد mp3 للتحميل - تحميل اناشيد - اناشيد جديدة
محتاج   محتاج




إضافة رد
 
أدوات الموضوع البحث بهذا الموضوع تقييم الموضوع طريقة العرض
  #1  
قديم(ـة) 05-29-2014, 03:12 PM
XRumerTest XRumerTest غير متصل
.. عضـو ممـ M7Taj ـيز ..
 


XRumerTest will become famous soon enough

I really love that this nail polish applies smoothly against the nails. It does not clump up really easily at all, which I certainly do appreciate. It is a little streaky, but not half as bad as many other pale polishes. Do keep in mind that while this polish may be a little streaky, pale polishes tend to be very streaky in general. Overall, I don't really recommend ELF's polishes for their quality, but it is a great way to get some new colors without paying a lot of dough. And even if this polish is not as pigmented as I would like it to be, many other pale polishes will not have any better opacity, so if you would like to have a lovely new color for spring, I would recommend this one. http://www.cafms.org/forum/contactus.php chanel bags replica http://www.arredahousedesign.it/public/dior.asp piumino peuterey chanel purses for sale cheap christian louboutin piumini peuterey isabel marant sneakers chanel bags outlet http://ristorantepizzeriafranco.it/C...ns/freerun.asp chanel handbags Johnny Manziel's quarterback guru has sold him on the Cleveland Browns and think he's worth a trade up to No. 1Johnny Manziel at the NFL Combine 2014: 'I play like I'm 10 feet tall'Do Cleveland Indians have right moves to reach October? Hey, Hoynsie!Johnny Manziel, a possibility for Cleveland Browns at No. 4, comes in at a shade under 6'0 at NFL Combine. nike free run 3 womens http://www.crnobelo.eu/burberry.php cheap china nba jerseys http://www.arredarsi.it/admin/hogan.asp giuseppe zanotti shop online giuseppe zanotti sale christian louboutin milano burberry borse uomo prada borse outlet louboutin mulberry outlet york adidas jeremy scott pas cher ï»؟The prettiest nail polish christian louboutin sale http://www.protezionecivilecunardo.i...i/peuterey.asp nike free shield 5.0 giubbotti peuterey chanel purses for sale http://www.presepi-cjmp.it/img/images.asp http://www.gabelliniauto.it/css/peuterey.asp converse all star sale scarpe zanotti outlet http://www.eagleserpentstudios.com/images/jerseys.asp jimmy choo outlet online burberry borse sconti Good day, ladies and gentlemen, and welcome to the Third Quarter 2012 Illumina Incorporated Earnings Conference Call. My name is Chanel, and I will be your operator for today. [ Instructions] As a reminder, this conference is being recorded for replay purposes.Thanks, Chanel. Good afternoon, everyone, and welcome to our earnings call for the third quarter of 2012. Before we get started, I'd like to announce that Rebecca Chambers, who has just joined Illumina, is our new Senior Director of Investor Relations. Rebecca comes to us from Myriad Genetics, where she was Head of Investor Relations and Corporate Communications. We're very excited to have Rebecca joined the team. Becca?Thank you, Marc. I'm very happy to have joined the team as well, and I look forward to working with our investors and analysts.During the call today, we will review the financial results released after the close of the market and offer commentary on our commercial activity. After which, we will host a question and answer session.Participating for Illumina today will be Jay Flatley, President and Chief Executive Officer; Marc Stapley, Senior Vice President and Chief Financial Officer; and Christian Henry, Senior Vice President and General Manager of our Genomic Solutions business.This call is being recorded, and the audio portion will be archived in the Investors section of our website. It is our intent that all forward looking statements regarding our expected financial results and commercial activity made during today's call will be protected under the Private Securities Litigation Reform Act of 1995.Forward looking statements are subject to risks and uncertainties. Actual events or results may differ materially from those projected or discussed. All forward looking statements are based upon current information available, and Illumina assumes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10 Q and 10 K.Before I turn the call over to Marc, I wanted to let you know that we will participate in the Piper Jaffray Annual Healthcare Conference on November 28. For those of you unable to attend this conference, we encourage you to listen to the webcast presentation, which will be available through the Investor Relations section of our website.With that, I will now turn the call back over to Marc.Thanks, Rebecca. During my section of today's call, I will review our third quarter financial results and our guidance for the rest of fiscal 2012. I will then turn the call over to Jay put the provide an update on our commercial progress and the state of our business and markets.We're pleased to report that our positive momentum continues, as this quarter marks the fourth consecutive quarter of sequential growth in both revenue and non GAAP EPS.In Q3, strong sales for HiSeq and an increase in delivery of whole genome service contracts led to revenue of $286 million, a 2% sequential increase. Included in these results is revenue of approximately $1 million from BlueGnome, the acquisition of which was announced on September 19.Year over year, revenue increased 21% due to the strength of our sequencing business. Instrument revenue for the third quarter was $82 million, up 14% sequentially, due to an increase in sequencing instruments, and up 15% year over year. The year over year growth was primarily due to the impact of MiSeq, which began shipments in Q3 of last year. Consumable revenue for the quarter was $177 million, down 4% sequentially and up 22% compared to the third quarter of 2011.Consumable revenue represented 62% of total revenue in line with Q3 last year and down slightly sequentially. The sequential decline has 2 primary components: the effect of reduced usage during the summer vacation season and the fact that Q2 was biased somewhat positively by success in our efforts to reduce reagent back orders.Services and other revenue, which includes genotyping and sequencing services as well as instrument maintenance contracts, was $23 million for the quarter, an 8% increase sequentially and a 54% increase year over year. Importantly, we shipped more than twice as many whole genome samples from our FastTrack Services lab as compared to the prior quarter, a record for our services business.Turning now to gross margin and operating expenses. I will highlight our adjusted non GAAP results, which exclude non cash stock compensation expense, headquarters relocation expense and other non cash items. I encourage you to review the GAAP reconciliation of non GAAP measures included in today's earnings release.Our adjusted gross margin for the third quarter was 70.5%. This compares to 70.9% last quarter and 68.9% in the third quarter of 2011. The sequential decline was primarily due to an increased mix of instrument revenue. Compared to the third quarter last year, the increase was driven by a higher mix of sequencing consumable revenue.Adjusted research and development expenses for the quarter were $46 million or 15.9% of revenue compared to 14.7% of revenue in the second quarter, with 17.4% of revenue in the third quarter of 2011. The sequential increase was primarily due to headcount additions with clinical trial expense to support the planned FDA submissions of MiSeq and our cyto products.Adjusted SG expenses were $56 million or 19.5% of revenue in the quarter. This is flat compared to the second quarter and down compared to 22.2% of revenue in the third quarter of 2011.Adjusted operating margins were 35.1% compared to 36.7% in the second quarter, again, primarily due to higher research and development expense, as well as the mix of instrument and consumable sales. On a year over year basis, operating margins expanded significantly due to a considerably higher revenue recorded this quarter.In the third quarter, we recognized approximately $4 million of adjusted other income, which contributed $0.02 to non GAAP EPS. Our non GAAP tax rate for the quarter was 33.9% compared to 34.4% in the third quarter of last year. R tax credit.Non GAAP net income was $54 million for the quarter and non GAAP EPS was $0.41. This compares to non GAAP net income and EPS of $30 million and $0.22, respectively, in the third quarter of 2011. The reported GAAP net income of $30 million or $0.22 per diluted share in the third quarter of 2012 compared to $20 million or $0.15 per diluted share in the prior year period. The current period results include $4 million of ongoing expenses related to Roche's unsolicited tender offer, as well as a $19.5 million charge associated with the relocation of our headquarters, as we completed the exit from our previous facility. Relocation charges are not expected to be material going forward.During the quarter, we generated cash from operations of $51 million. Capital expenditures were just under $18 million, resulting in approximately $34 million of free cash flow. This amount is lower than the $68 million of free cash flow in the third quarter of last year due to changes in working capital associated with the timing of shipments. Sequentially, free cash flow was impacted by higher accounts receivable levels.DSO increased to 69 days compared to 61 days last quarter, also driven primarily by the timing of shipments. We ended the quarter with approximately $1.2 billion in cash and short term investments after using $88 million of cash to acquire BlueGnome.We are pleased with our financial performance for the first 3 quarters of 2012. The impact of the academic and research funding environment from this year's results is largely known due to the continuing resolution being signed into law. With the fiscal cliff and presidential election on the horizon, we do remain cautious. As a result, we are projecting fiscal 2012 revenue in the range of $1.134 billion to $1.144 billion, which equates to fourth quarter revenue of approximately $295 million to $305 million.Fiscal 2012 non GAAP earnings per fully diluted share are expected to be in the range of $1.54 to $1.59 or approximately $0.38 to $0.43 in the fourth quarter. Importantly, these projections include expected gross margins of about 70% for the full year; the impact of the R tax credit, whether passed or not; additional share repurchases; and BlueGnome revenue of approximately $5 million. BlueGnome's impact on EPS is expected to be neutral in the fourth quarter.
الرد باقتباس
  #2  
قديم(ـة) 01-13-2018, 05:31 PM
XRumerTest XRumerTest غير متصل
.. عضـو ممـ M7Taj ـيز ..
 


XRumerTest will become famous soon enough
الافتراضي Test, just a test

Hello. And Bye.
الرد باقتباس
  #3  
قديم(ـة) 01-13-2018, 05:39 PM
XRumerTest XRumerTest غير متصل
.. عضـو ممـ M7Taj ـيز ..
 


XRumerTest will become famous soon enough
الافتراضي Test, just a test

Hello. And Bye.
الرد باقتباس
إضافة رد

الإشارات المرجعية

أدوات الموضوع البحث بهذا الموضوع
البحث بهذا الموضوع:

بحث متقدم
طريقة العرض قيّم هذا الموضوع
قيّم هذا الموضوع:



الساعة الآن +3: 05:15 PM.


Powered by vBulletin® Version 3.8.4
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.

محتاج محتاج
قمت بتقييم هذا الموضوع مسبقاً: